Cancer Home > Mutamycin and Breastfeeding
It is generally recommended that women not breastfeed during treatment with Mutamycin (mitomycin). Although it is unknown if this drug passes through breast milk, it might put a nursing infant at risk for potentially serious problems. Because every woman's situation is different, talk to your healthcare provider about the benefits and risks of using this drug while nursing.
Mutamycin® (mitomycin) is a prescription anticancer medication approved to treat stomach and pancreatic cancer. It may also be used off-label to treat other types of cancer, including bladder cancer.
At this time, it is unknown if Mutamycin passes through breast milk. Therefore, you should talk to your healthcare provider before breastfeeding a child during treatment.
No research has been done to see if Mutamycin passes through breast milk or if it would harm a nursing child. Although this lack of information is frustrating, it is important to note that most medicines are not studied in breastfeeding women, as doing so could expose a child, who would not otherwise benefit from the medicine, to potential harm.
Many medicines pass through breast milk. Based on the properties of Mutamycin, it is expected to pass through breast milk to some extent. Because this drug is associated with potentially serious side effects, it is generally recommended that women not breastfeed during Mutamycin treatment.
You should discuss breastfeeding and Mutamycin use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.